Skip to main content

Search form

You are here

Georgia Doris Tomaras, PhD

Professor in Surgery
Professor in Immunology
Professor in Molecular Genetics and Microbiology
Division: 
Surgical Sciences
Faculty Lab: 
Immune Responses and Virology Laboratory
Office: 300 N Duke St, Durham, NC 27701
Campus Mail: DUMC Box 104777 DUMC, Bay 47 Carmichael Bldg, 300 N. Duke St, Durham, NC 27701

Dr. Georgia Tomaras is a tenured Professor of Surgery, Professor of Immunology, Professor of Molecular Genetics and Microbiology and is a Fellow of the American Academy of Microbiology (AAM) and a Fellow of the American Association for the Advancement of Science (AAAS).  Dr. Tomaras is Co-Director of the Center for Human Systems Immunology (CHSI) Duke University and Director of the Duke Center for AIDS Research (CFAR). Her national and international leadership roles include: Executive Management Team (EMT) leader and mPI for the HIV Vaccine Trials Network (HVTN); Director of Lab Sciences (HVTN); and Chair of NIH Vaccine Research Center (VRC) Board of Scientific Counselors. Her prior leadership roles include serving as the Director of Research, Duke Human Vaccine Institute (DHVI); Director of the DHVI Training Program; Associate Director of DHVI Research; Co-Director of the Interdisciplinary Research Training Program in AIDS (IRTPA) Duke; Chair of the National Institutes of Health (NIH) AIDS Vaccine Research Subcommittee (AVRS), and Advisory Counsel member of the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID). Dr. Tomaras’ primary research focus is deciphering mechanisms of protective human immunity and identification of immune correlates of protection to further development of effective vaccines against infectious diseases.  

 

Education and Training

  • Postdoctoral Fellowship, Center For Aids Research, Department Of Surgery, Duke University, 1998 - 2001
  • Ph.D., State University of New York Upstate Medical University, 1998

In the News

Selected Grants

Publications

Mielke, Dieter, Sherry Stanfield-Oakley, Shalini Jha, Taylor Keyes, Adam Zalaquett, Brooke Dunn, Nicole Rodgers, et al. “Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulation.” Cytometry A 101, no. 6 (June 2022): 483–96. https://doi.org/10.1002/cyto.a.24552.

Full Text

Julg, Boris, Kathryn E. Stephenson, Kshitij Wagh, Sabrina C. Tan, Rebecca Zash, Stephen Walsh, Jessica Ansel, et al. “Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.” Nat Med 28, no. 6 (June 2022): 1288–96. https://doi.org/10.1038/s41591-022-01815-1.

Full Text

Welbourn, Sarah, Srirupa Chakraborty, Jie E. Yang, Anne S. Gleinich, Sailaja Gangadhara, Salar Khan, Courtney Ferrebee, et al. “A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence.” Plos Pathog 18, no. 5 (May 2022): e1010488. https://doi.org/10.1371/journal.ppat.1010488.

Full Text

Sahoo, Anusmita, Edgar A. Hodge, Celia C. LaBranche, Tiffany M. Styles, Xiaoying Shen, Narayanaiah Cheedarla, Ayalnesh Shiferaw, et al. “Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies.” Cell Rep 38, no. 9 (March 1, 2022): 110436. https://doi.org/10.1016/j.celrep.2022.110436.

Full Text

Wang, Shixia, Nicole L. Yates, Justin Pollara, Yegor Voronin, Sherry Stanfield-Oakley, Dong Han, Guangnan Hu, et al. “Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV.” Npj Vaccines 7, no. 1 (February 9, 2022): 18. https://doi.org/10.1038/s41541-022-00441-9.

Full Text

Mielke, Dieter, Sherry Stanfield-Oakley, Bhavesh Borate, Leigh H. Fisher, Katelyn Faircloth, Marina Tuyishime, Kelli Greene, et al. “Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies.” J Virol 96, no. 2 (January 26, 2022): e0164321. https://doi.org/10.1128/JVI.01643-21.

Full Text

Lakhashe, Samir K., Mario Amacker, Dinesh Hariraju, Hemant K. Vyas, Kyle S. Morrison, Joshua A. Weiner, Margaret E. Ackerman, et al. “Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges.” Front Immunol 13 (2022): 788619. https://doi.org/10.3389/fimmu.2022.788619.

Full Text

Saunders, Kevin O., Norbert Pardi, Robert Parks, Sampa Santra, Zekun Mu, Laura Sutherland, Richard Scearce, et al. “Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates.” Npj Vaccines 6, no. 1 (November 6, 2021): 136. https://doi.org/10.1038/s41541-021-00397-2.

Full Text

Dahora, Lindsay C., Marije K. Verheul, Katherine L. Williams, Celina Jin, Lisa Stockdale, Guy Cavet, Eldar Giladi, et al. “Salmonella Typhi Vi capsule prime-boost vaccination induces convergent and functional antibody responses.” Sci Immunol 6, no. 64 (October 29, 2021): eabj1181. https://doi.org/10.1126/sciimmunol.abj1181.

Full Text

Hastie, Kathryn M., Haoyang Li, Daniel Bedinger, Sharon L. Schendel, S Moses Dennison, Kan Li, Vamseedhar Rayaprolu, et al. “Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.” Science 374, no. 6566 (October 22, 2021): 472–78. https://doi.org/10.1126/science.abh2315.

Full Text

Pages